ASCO

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Endpoints
ASCO
IDO inhibitors
CAR-T
PDL-1 inhibitors
Merck
Incyte
NewLink Genetics
Novartis
Juno Therapeutics
Bristol-Myers Squibb
Flag link:
AstraZeneca looks to DNA damage-response drugs for edge in oncology
AstraZeneca looks to DNA damage-response drugs for edge in oncology
BioPharma Dive
AstraZeneca
oncology
ASCO
Lynparza
Flag link:
Roche Still Waiting For The Big Push
Roche Still Waiting For The Big Push
Seeking Alpha
Roche
ASCO
immuno-oncology
Amgen
Merck
Bristol-Myers Squibb
Flag link:
Lilly's Alimta gets rating boost in update to ASCO's drug scorecard
Lilly's Alimta gets rating boost in update to ASCO's drug scorecard
Fierce Pharma
Eli Lilly
Alimta
ASCO
lung cancer
Flag link:
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
24/7 Wall St
biotech
ASCO
Immunogen
Exelixis
Oncothyreon
CTI BioPharma
Immunomedics
Vascular Biogenics
Flag link:
Top-Performing Biotech and Drug Stocks During ASCO '15
Top-Performing Biotech and Drug Stocks During ASCO '15
TheStreet.com
ASCO
Ignyta
Immunogen
Puma Biotechnology
AbbVie
Roche
Bristol-Myers Squibb
Seattle Genetics
Juno Therapeutics
Flag link:
Amgen: The Quiet Winner
Amgen: The Quiet Winner
Barron's
Amgen
ASCO
Kyprolis
Flag link:
ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate
ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate
Forbes
ASCO
cancer immunotherapy
glioblastoma multiforme
Merck
Genentech
Celldex Therapeutics
Flag link:
16 Biotech Stocks Moving Off The ASCO Conference
16 Biotech Stocks Moving Off The ASCO Conference
Yahoo/Benzinga
biotech
ASCO
Bristol-Myers Squibb
Immunogen
Oncothyreon
Clovis Oncology
CTI BioPharma
Exelixis
Roche
Amgen
AstraZeneca
Puma Biotechnology
Vascular Biogenics
Immunomedics
Momenta
Eli Lilly
Juno Therapeutics
Express Scripts
Flag link:
The 4 Overlooked Winners of ASCO
The 4 Overlooked Winners of ASCO
24/7 Wall St
ASCO
Bristol-Myers Squibb
AbbVie
Aveo Pharmaceuticals
Ignyta
Flag link:
Merck KGaA sees immunotherapy drug holding its own in cancer race
Merck KGaA sees immunotherapy drug holding its own in cancer race
Yahoo/Reuters
Merck KGaA
avelumab
Pfizer
ASCO
cancer immunotherapy
Flag link:
Pfizer's Ibrance Takes Another Giant Leap Forward
Pfizer's Ibrance Takes Another Giant Leap Forward
Investopedia
Pfizer
Ibrance
ASCO
breast cancer
Flag link:
The Biggest Selling Cancer Drugs In 2020 Show Significant Change Expected In Five Short Years
The Biggest Selling Cancer Drugs In 2020 Show Significant Change Expected In Five Short Years
Forbes
ASCO
PDL-1 inhibitors
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Flag link:
ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab
TheStreet.com
ASCO
Oncothyreon
Immunogen
Bristol-Myers Squibb
Merck
Clovis Oncology
Roche
CTI BioPharma
Celldex Therapeutics
Puma Biotechnology
Express Scripts
Flag link:
Pfizer gaining market share in oncology: CEO
Pfizer gaining market share in oncology: CEO
CNBC
Pfizer
oncology
Pharma CEOs
Ian Read
ASCO
Flag link:
At ASCO: Bristol-Myers Rises on More Data About Cancer Drug
At ASCO: Bristol-Myers Rises on More Data About Cancer Drug
Barron's
ASCO
Bristol-Myers Squibb
Opdivo
Flag link:
ASCO 15: The top 10 setbacks, advances and head scratchers
ASCO 15: The top 10 setbacks, advances and head scratchers
Fierce Biotech
ASCO
Celldex Therapeutics
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Clovis Oncology
AstraZeneca
Genentech
Flag link:
Top Oncologist To Convention Of Doctors, Pharma Execs: New Cancer Treatments Cost Too Much
Top Oncologist To Convention Of Doctors, Pharma Execs: New Cancer Treatments Cost Too Much
Forbes
ASCO
physicians
drug pricing
drug costs
Flag link:
6 Key Cancer Winners From ASCO Presentations
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Flag link:
Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
TheStreet.com
Oncothyreon
breast cancer
ASCO
ONT-380
HER2-positive metastatic breast cancer
Flag link: